Assignment Mental Health Disordersa 38 Year Old Woman Presen

Assignment Mental Health Disordersa 38 Year Old Woman Presents To the Assignment Mental Health Disordersa 38 Year Old Woman Presents To the

A 38-year-old woman presents to the office with complaints of weight loss, fatigue, and insomnia of 3-month duration. She reports that she has been feeling gradually more tired and staying up late at night because she can’t sleep. She does not feel that she is doing as well in her occupation as a secretary and states that she has trouble remembering things. She does not go outdoors as much as she used to and cannot recall the last time she went out with friends or enjoyed a social gathering. She feels tired most of the week and states she feels that she wants to go to sleep and frequently does not want to get out of bed. She denies any recent medication, illicit drug, or alcohol use. She feels intense guilt regarding past failed relationships because she perceives them as faults. She states she has never thought of suicide, but has begun to feel increasingly worthless. Her vital signs and general physical examination are normal, although she becomes tearful while talking. Her mental status examination is significant for depressed mood, psychomotor retardation, and difficulty attending to questions. Laboratory studies reveal a normal metabolic panel, normal complete blood count, and normal thyroid functions.

Paper For Above instruction

The presentation of this 38-year-old woman suggests a diagnosis of major depressive disorder (MDD), which is characterized by persistent sadness, loss of interest, and a variety of physical and cognitive symptoms that impair daily functioning. Depression is one of the most common psychiatric disorders globally, with significant impacts on quality of life, employment, and social relationships. The patient's symptoms—weight loss, fatigue, insomnia, cognitive impairments, social withdrawal, feelings of worthlessness, and guilt—are hallmark features of major depressive episodes, aligning with diagnostic criteria outlined in DSM-5 (American Psychiatric Association, 2013). Her normal physical and laboratory findings help exclude other medical conditions that can mimic depression, such as hypothyroidism, which was ruled out with normal thyroid function tests.

Depression often presents with affective, cognitive, and somatic symptoms. In this patient, the pervasive depressed mood, psychomotor retardation, and anhedonia (loss of interest) are central. The cognitive deficits, such as forgetfulness, are common in depression, often reflecting concentration difficulties rather than neurodegenerative processes. Her social withdrawal and diminished engagement highlight the interpersonal toll of the disorder, leading to reduced social support, which can exacerbate depressive

symptoms (Otte et al., 2016).

The next step in management involves confirming the diagnosis and considering both pharmacological and psychotherapeutic interventions. Given her significant symptoms and functional impairment, initiating antidepressant therapy, such as selective serotonin reuptake inhibitors (SSRIs), is appropriate. SSRIs like sertraline or escitalopram are first-line treatments due to their efficacy and tolerability (Gelenberg et al., 2010). Additionally, psychotherapy, particularly cognitive-behavioral therapy (CBT), should be considered to address maladaptive thought patterns and improve coping skills (Hofmann, Asnaani, Vonk, Sawyer, & Fang, 2012). Monitoring her response to treatment and potential adverse effects is essential, alongside regular follow-up to assess symptom remission and functional recovery.

Important considerations include the risk of suicidality, especially since the patient reports feelings of worthlessness, although she currently denies suicidal ideation. Close monitoring for worsening mood, emergence of suicidal thoughts, or adverse drug reactions is vital. Patient education about medication adherence, side effects, and the importance of therapy engagement is necessary. Potential complications include medication side effects such as gastrointestinal disturbances, sexual dysfunction, or increased suicidality in some cases, particularly during initial treatment phases, emphasizing the importance of close follow-up (Gelenberg et al., 2010). Furthermore, addressing social isolation and encouraging lifestyle modifications like regular exercise and social engagement may augment treatment outcomes.

In summary, this patient's presentation is most consistent with major depressive disorder. The treatment plan should include initiating antidepressant medication combined with psychotherapy, with vigilant monitoring for safety and efficacy. Recognizing and managing depression early can significantly improve her prognosis and overall functioning, preventing the potential progression to chronicity or severity with recurrent episodes.

References

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.).

Gelenberg, A. J., et al. (2010). Practice guideline for the treatment of patients with major depressive disorder. American Journal of Psychiatry, 167(10), 1-44.

Hofmann, S. G., Asnaani, A., Vonk, I. J., Sawyer, A. T., & Fang, A. (2012). The efficacy of cognitive

behavioral therapy: A review of meta-analyses. Cognitive Therapy and Research, 36(5), 427-440.

Otte, C., et al. (2016). Major depressive disorder. Nature Reviews Disease Primers, 2(1), 16065.

Fava, G. A. (2003). Diagnosis and definition of treatment-resistant depression. Biological Psychiatry, 53(8), 649-659.

Kennedy, S. H., et al. (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adult depression. Canadian Journal of Psychiatry, 61(9), 540-560.

Rush, A. J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917.

Trivedi, M. H., et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. The British Journal of Psychiatry, 189(3), 200-207.

Zimmerman, M., et al. (2013). Development and validation of a new clinical scale for depression: The patient-rated Montgomery–Asberg Depression Rating Scale. Journal of Clinical Psychiatry, 74(6), 610-618.

Harmer, C. J., et al. (2017). How can antidepressants work? Insights from neuroimaging studies. Biological Psychiatry, 82(8), 574-583.